samedan logo
 
 
 
spacer
home > pmps > summer 2008 > seeking closure
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Seeking Closure

With growing concerns of interactions between drug products and container closure systems, pharmaceutical companies desire an ideal elastomeric closure. Prior to this increased awareness, the role of elastomeric closures was quite basic. This allowed pharmaceutical companies to develop standard packaging components for their portfolio of injectable drug products. The role of a standard elastomeric closure was limited to confining a pharmaceutical within a given area (for example, vial or syringe), maintaining a seal for vials or syringes, and permitting proper removal of pharmaceuticals via a hypodermic needle.

However, in recent decades, more demands come from pharmaceutical companies to their suppliers, including improved compounds and coatings, more specific closures designs, manufacturing facilities that are GMP-compliant, and validated wash processes that comply with the requirements of FDA and EU guidances. This article discusses the choices pharmaceutical companies are required to review when selecting an elastomeric closure.

CLOSURE DESIGN

Typically, one of the most fundamental decisions to make when choosing an elastomeric closure is the geometrical design. This statement holds true for vial stoppers (includes serum and lyophilisation stoppers) more than it does for syringe components (plungers/pistons, tip caps and needle covers). Vial stoppers are traditionally designed in accordance with ISO standards ISO 8362-2 and ISO8362-5, which promotes compatibility with ISO standard ISO 8362-1 for vials.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Douglas Cusato is a Technical Support Manager with Helvoet Pharma. He joined Helvoet Pharma in August of 2006 and is responsible for assisting customers with technical issues such as extractables and leachables, rubber formulation and closure design recommendations, and closure coatings. He holds a Bachelor degree in Chemistry from Rutgers University, Camden, NJ, with an emphasis on biochemistry. Commencing September 2007 he began his Masters degree at Rutgers University, Camden, NJ focusing on polymer/material chemistry.
spacer
Douglas Cusato
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Memo Therapeutics AG collaborate on the fast-track manufacturing of a SARS-CoV-2- neutralizing antibody for the therapy of COVID-19

Vilnius, Lithuania, and Schlieren, Switzerland – August 11, 2020 – Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Swiss biotech company Memo Therapeutics AG (MTx), announce a new partnership to manufacture MTx’s therapeutic COVID-19 antibody candidate in a 4-month fast-track process approved by regulatory authorities.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement